Literature DB >> 25539800

Tigecycline : a critical safety review.

Quanhathai Kaewpoowat1, Luis Ostrosky-Zeichner.   

Abstract

INTRODUCTION: The emergence of multidrug-resistant (MDR) infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline , a broad spectrum antibiotic covering against many MDR organisms, has been widely used. However, recent meta-analysis studies have raised a concern for its efficacy and safety. Reviewing tigecycline safety data would enhance the appropriate use of this medication. AREAS COVERED: This article reviews the safety profile of tigecycline, including its side effects and drug interactions. EXPERT OPINION: The increased mortality associated with tigecycline is not yet well understood. Based on current evidence, alternative options must be prioritized over tigecycline if available. When tigecycline use is warranted, vigilant observation to identify any breakthrough infections and careful monitoring of progression of the original infection are highly recommended. Considering a second agent (either for synergism or enhancing coverage) may be required.

Entities:  

Keywords:  adverse reactions; drugs interactions; safety evaluation; tigecycline

Mesh:

Substances:

Year:  2014        PMID: 25539800     DOI: 10.1517/14740338.2015.997206

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  19 in total

1.  Targeting mitochondrial respiration selectively sensitizes pediatric acute lymphoblastic leukemia cell lines and patient samples to standard chemotherapy.

Authors:  Xuedong Fu; Wei Liu; Qian Huang; Yanjun Wang; Huijuan Li; Ying Xiong
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Jennifer H Han; Pranita D Tamma
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

5.  Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Authors:  Juan Hu; Yong-Hong Xiao; Yi Zheng; Yang-Xiao Lai; Xue-Ling Fang; Qiang Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-04-30       Impact factor: 2.953

6.  Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.

Authors:  Lei Zha; Lingling Pan; Jun Guo; Neil French; Elmer V Villanueva; Boris Tefsen
Journal:  Adv Ther       Date:  2020-01-31       Impact factor: 3.845

7.  Tigecycline application in a 3-month-old infant with multiple drug resistant Klebsiella pneumonia: a case report.

Authors:  Cheng Peng; Xiaofeng Wang; Jiangwei Zhang; Yi Jiang; Xinlin Hou
Journal:  Gut Pathog       Date:  2018-06-22       Impact factor: 4.181

8.  A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii.

Authors:  Yu-Qing Fang; Ru-Cai Zhan; Wei Jia; Bao-Qing Zhang; Jian-Jun Wang
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

9.  A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.

Authors:  Xiaoqin Wu; Ping Zhao; Liang Dong; Xiuhong Zhang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage.

Authors:  Ying Xiong; Wei Liu; Qian Huang; Jierong Wang; Yanjun Wang; Huijuan Li; Xuedong Fu
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.